Testing a new drug combination for recurrent solid tumors
Part of Brain & nervous system, Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This early-phase trial tests a new combination of drugs (CICS-1 and SPM-011) along with a special imaging scan to see if they can help people with hard-to-treat cancers that have come back. It may be an option if standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer (except a rare skin cancer called cutaneous angiosarcoma).
- Your tumor can be measured on scans and has come back after treatment, and it cannot be surgically removed.
- Standard treatments are not working well for you.
- You are fully active or only slightly limited (ECOG score 0 or 1).
- You have not had high-dose radiation (>65 Gy) to the tumor area before.
- You do not have another active cancer or serious health problems that would interfere with treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new study drugs (SCTB41 and SCTB39-1) given together, sometimes with standard treatment, to see if they are safe and effective against advanced solid tumors. If you join, you will receive these drugs and be monitored for how well they fight the cancer.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests a new combination of two investigational drugs (SCTB41 and SCTB39G), sometimes given with standard treatment, for advanced solid tumors. The goal is to see if this approach can shrink tumors and control the cancer, and it may be an option for people who have exhausted standard treatments.
This trial tests a new drug, SCTB39G, for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it can shrink tumors and improve survival, and to find the best dose. Participation involves regular treatment and check-ups.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Hear when a new Thoracic Solid Malignant Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.